Matthew J During

USPTO Granted Patents = 68 (Patent Applications = 63)

CIPO Patents = 1 (Patent Applications = 29)

EPO Patents = 5 (Patent Applications = 30)

Average Co-Inventor Count = 1.2

ph-index = 13

Forward Citations = 750(Granted Patents)

Forward Citations (Not Self Cited) = 561(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Philadelphia, PA (US) (2001 - 2011)
New York, NY (US) (2010 - 2012)
Columbus, OH (US) (2011 - 2017)
Weston, CT (US) (2001 - 2023)
Darien, CT (US) (2023 - 2024)

Company Filing History:

51 out of 51

Ovid Therapeutics Inc.

Thomas Jefferson University

Oxford University Innovation Limited

patents

6. 1 out of 827

The Ohio State University

patents

7. 1 out of 1

Auckland Technology Enabling Corporation

patent

8. 1 out of 712

The Rockefeller University

patents

9. 1 out of 1

Neurologix Research, Inc.

patent

10. 5 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

Developmental Disorders

Gaboxadol

Epileptic Disorders

Seizure Disorders

Tourette Syndrome

Angelman Syndrome

PDE10A Inhibitors

Tinnitus

Behavioral Syndromes

Critical Care Treatment

Gene Therapy

Insomnia

68 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12465597 - Methods of treating developmental disorders with gaboxadol (2025-11-11),

2. 12285397 - Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders (2025-04-29),

3. 12144801 - Methods and compositions for treatment of epileptic disorders (2024-11-19),

4. 12109201 - Methods and compositions for treatment of epileptic disorders (2024-10-08),

5. 11918563 - Methods and compositions for treatment of epileptic disorders (2024-03-05),

6. 11918551 - Methods of treating seizure disorders and Prader-Willi syndrome (2024-03-05),

7. 11903930 - Methods and compositions for treatment of epileptic disorders (2024-02-20),

8. 11806336 - Methods and compositions for treatment of epileptic disorders (2023-11-07),

9. 11771671 - Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction (2023-10-03),

10. 11761006 - Use of MIR101 or MIR128 in the treatment of seizure disorders (2023-09-19),

11. 11690829 - Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder (2023-07-04),

12. 11660277 - Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders (2023-05-30),

13. 11395817 - Methods and compositions for treatment of epileptic disorders (2022-07-26),

14. 11364228 - Gaboxadol for therapeutic treatment of 1p36 deletion syndrome (2022-06-21),

15. 11291658 - Use of gaboxadol in the treatment of diabetes and related conditions (2022-04-05),

Title: Matthew J During: Innovator in Epileptic Disorder Treatment

Introduction

Matthew J During, based in New York, NY, is a prolific inventor with a remarkable portfolio of 66 patents. His work primarily focuses on enhancing treatment methods for epileptic disorders, showcasing his commitment to medical advancements.

Latest Patents

Among his latest contributions to the field are pioneering patents related to the use of allosteric modulators and gaboxadol for treating epileptic disorders. These innovative methods aim to provide effective treatments for individuals in need, reflecting his dedication to improving patient outcomes.

Career Highlights

Throughout his career, Matthew has been associated with Ovid Therapeutics Inc., where his expertise in neurological science has greatly contributed to the company's mission of developing innovative therapies. His extensive patent portfolio underscores his significant impact in the realm of medical research.

Collaborations

Matthew has had the privilege of collaborating with esteemed colleagues such as Michael G Kaplitt and Anna Kazanchyan. These partnerships have fostered a dynamic exchange of ideas, further propelling advancements in epilepsy treatment methodologies.

Conclusion

Matthew J During stands out as a noteworthy inventor whose works have the potential to transform the lives of those suffering from epileptic disorders. His contributions highlight the importance of innovation in medicine, paving the way for future discoveries that can enhance therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.